02 Sep Health Moboxen 40mg (Mobocertinib): Targeted Therapy for EGFR Exon 20 NSCLC 02/09/2025 By Dipesh Moboxen 40mg is a brand name for the drug Mobocertinib, an oral medication designed specifically to treat a rare subset of non-small ce...Continue reading
01 Sep Health Alkixen 250mg: Improving Quality of Life for Cancer Patients 01/09/2025 By Dipesh Crizotinib, marketed under the brand name Alkixen 250mg, is a targeted therapy medication primarily utilized in oncology for treating s...Continue reading
19 Aug Health Adakras 200mg Targeted Therapy for KRAS G12C Mutation in NSCLC 19/08/2025 By Dipesh Adakras 200mg is a generic formulation of Adagrasib, a targeted therapy. Adagrasib is an oral, irreversible inhibitor of the KRAS G12C ...Continue reading